Department of Nutrition, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Department of Nutritional Sciences, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Phytother Res. 2024 Sep;38(9):4667-4674. doi: 10.1002/ptr.8273. Epub 2024 Aug 5.
This randomized clinical trial was conducted to evaluate the effects of silymarin supplementation on glycemic indices and serum lipid profile in type 2 diabetes mellitus (T2DM) patients. In this open-label randomized clinical trial study, 48 patients with T2DM were eligible to participate for 12 weeks and were divided into two groups randomly: 24 subjects in the intervention (received three 140 mg silymarin capsules daily and diet plan) and 24 in control (received a diet plan). Fasting blood samples and anthropometric data were collected, and glycemic indices and lipid profiles were determined at baseline and at the end of the study. Out of 60 patients included in the clinical trial, 48 people completed the study. In comparing silymarin and control groups before and after the study, a significant reduction was observed in weight and body mass index. However, after adjustment, no significant difference was seen between the two groups. Furthermore, daily consumption of three capsules of 140 mg silymarin for 12 weeks did not show any significant difference on the level of fasting blood sugar (p = 0.789), HbA1c (p = 0.719), and lipid profile. The findings of the present study show that silymarin did not lead to changes in the level of glycemic index and lipid profile in patients with T2DM.
这项随机临床试验旨在评估水飞蓟素补充剂对 2 型糖尿病（T2DM）患者血糖指数和血清血脂谱的影响。在这项开放标签随机临床试验研究中，48 名 T2DM 患者有资格参加为期 12 周的研究，并随机分为两组：24 名干预组（每天服用三粒 140mg 的水飞蓟素胶囊和饮食计划）和 24 名对照组（接受饮食计划）。在基线和研究结束时收集空腹血样和人体测量数据，并确定血糖指数和血脂谱。在 60 名纳入临床试验的患者中，有 48 人完成了研究。在比较研究前后的水飞蓟素组和对照组，体重和体重指数均显著降低。然而，调整后，两组之间没有显著差异。此外，每天服用三粒 140mg 的水飞蓟素胶囊 12 周，对空腹血糖（p=0.789）、HbA1c（p=0.719）和血脂谱水平没有显著影响。本研究的结果表明，水飞蓟素不会导致 T2DM 患者血糖指数和血脂谱水平发生变化。
